BioNTech SE (BNTX)
NASDAQ:BNTX
Earnings Data
Report Date
May 11, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-2.58Last Year’s EPS
-2.03Same Quarter Last Year
Strong Buy
Based on 16 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Overall the call presented a constructive picture: BioNTech outperformed its raised 2025 guidance, preserved a very strong cash position (EUR 17.2 billion), advanced a broad late-stage oncology pipeline with multiple planned readouts in 2026–2030, and executed strategic deals to derisk programs. Offsetting this, management guided materially lower revenues for 2026 (EUR 2.0–2.3bn vs EUR 2.9bn in 2025), highlighted near-term increases in R&D and SG&A to support oncology launches, reported an adjusted net loss (EUR 117m) and disclosed a trial discontinuation in one indication. The founders' planned transition to a new company introduces execution uncertainty but is framed as an orderly process through end-2026. On balance, the positive operational progress, portfolio de-risking and very strong liquidity outweigh the near-term revenue headwinds and costs.Company Guidance
COVID Vaccine Leadership and Market Share
Launched a variant-adapted COVID vaccine with Pfizer; product distributed in over 180 countries and holds more than 50% market share in major markets. Management describes COMIRNATY as a cash-generative franchise with favorable economics under the Pfizer collaboration.
2025 Revenues and BMS Payment Recognition
Total reported revenues for 2025 were EUR 2.9 billion, a slight increase year-over-year despite declines in COVID-19 vaccine revenues. The company recognized EUR 613 million in noncontingent upfront/anniversary payments from the BMS collaboration in 2025.
Strong Liquidity Position
Ended 2025 with EUR 17.2 billion in cash, cash equivalents and securities, providing a substantial balance-sheet buffer to fund late-stage development and commercial preparations.
Pipeline Advancement and Clinical Footprint
Advanced oncology pipeline: more than 4,000 patients enrolled across Phase II and Phase III studies, initiation of global Phase III trials in NSCLC, SCLC and TNBC, and expectation of multiple late-stage event-driven readouts in 2026. Management anticipates a sustained cadence of event-driven readouts from 2026–2030.
Novel-Novel Combination Development
More than 10 novel-novel combination trials with Pumitamig in progress; three-wave development plan (establish, expand, elevate) with explicit registrational-first strategies and plans to nominate pivotal Pumitamig+ADC combos informed by multifactor screens.
Strategic Partnerships and Acquisitions
Key strategic deals executed to de-risk and accelerate programs: collaboration with BMS on Pumitamig, acquisition of Biotheus to gain full rights to Pumitamig, and acquisition of CureVac to strengthen mRNA capabilities.
Cost Discipline and Adjusted Profitability Measure
R&D spend in 2025 was approximately EUR 2.1 billion (a slight decrease year-over-year) aided by portfolio prioritization and cost-sharing with BMS. On a supplemental adjusted non-IFRS basis (excluding legal, impairments, restructuring, bargain purchase, divestiture items), BioNTech reported an adjusted net loss of EUR 117 million for 2025.
2026 Focus and Preparedness for Commercialization
Management outlined 2026 priorities: accelerate late-stage oncology development, build momentum for combination-based Pumitamig trials, shift toward tumor-centric development in high-incidence cancers, and continue commercial/market access build-out ahead of potential launches.
BNTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BNTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 10, 2026 | $102.16 | $83.89 | -17.88% |
Nov 03, 2025 | $103.91 | $103.96 | +0.05% |
Aug 04, 2025 | $107.34 | $110.03 | +2.51% |
May 05, 2025 | $104.94 | $101.10 | -3.66% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BioNTech SE (BNTX) report earnings?
BioNTech SE (BNTX) is schdueled to report earning on May 11, 2026, Before Open (Confirmed).
What is BioNTech SE (BNTX) earnings time?
BioNTech SE (BNTX) earnings time is at May 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BNTX EPS forecast?
BNTX EPS forecast for the fiscal quarter 2026 (Q1) is -2.58.
